SNIFF 120: Study of Nasal Insulin to Fight Forgetfulness (120 Days)

• Status: Completed
• Trial end date: 2011-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to find out if insulin, when administered as a "nasal spray" into the nasal passages, improves memory in adults with mild cognitive impairment (MCI) or Alzheimer's disease.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Washington
• Collaborator: National Institute on Aging (NIA)
• Treatments: Insulin; Insulin, Globin Zinc

Criteria

Inclusion Criteria:

• Age 55 or greater

• Good physical health

• Memory impairment with a diagnosis of mild cognitive impairment (MCI) or Alzheimer's disease (AD)

• Participants on stable doses of Memantine (Namenda) or cholinesterase inhibitors will be eligible

Exclusion Criteria:

• Chronic sinus problems/allergies with chronic use of nasal decongestants or antihistamines

• Significant neurologic disease that might affect cognition (other than AD), such as stroke, Parkinson's disease, multiple sclerosis, severe head injury with loss of consciousness for more than 30 minutes or with permanent neurologic symptoms

• Significant medical illness or organ failure, such as uncontrolled hypertension or cardiovascular disease, chronic obstructive pulmonary disease, liver disease, or kidney disease

• Preexisting diabetes or current or previous use of hypoglycemic agents or insulin; participants will be excluded if they have a fasting blood sugar greater than 165 on baseline OGTT

• Clinically significant elevations in liver function tests, cholesterol, or triglycerides

• Major psychiatric disorders (e.g., untreated major depression and schizophrenia)

• Chronic use of the following types of medications: anti-psychotic, anxiolytic, and opiates